Human genome editing: ensuring responsible research
By Editorial,
The Lancet
| 03. 18. 2023
In 2018, during the Second International Summit on Human Genome Editing in Hong Kong, Jiankui He shocked the world by announcing the birth of two children whose genomes he had edited using CRISPR technology. Following widespread condemnation and a criminal investigation, he was sentenced to 3 years in prison. The case caused international outcry and brought to the fore the need to reconsider the serious ethical, scientific, and social issues of heritable human genome editing. As science advances, especially in non-heritable, somatic gene editing for treatment of previously incurable diseases, regulatory gaps are becoming exposed. Governance of gene editing research was a major discussion point at the Third International Human Genome Editing Summit in London, on March 6–8, with widespread recognition for the need to build on existing guidelines to develop global standards for governance and oversight of human genome editing. As He's unconscionable actions showed, the ethical and scientific risks are substantial.
Gene editing regulations must consider the aims and consequences of the different practices involved. Somatic genome editing interventions (eg, targeted therapies such as chimeric antigen receptor T...
Related Articles
By Sarojini Nadimpally and Gargi Mishra, The Wire | 12.15.2024
In-vitro fertilisation (IVF) as assisted reproductive technology (ART) has been in vogue for quite a few decades now. While IVF has been hailed as a significant scientific advancement, with many advantages, here are some limitations which bear keeping in mind...
Image by Mohamed Hassan from Pixabay
It is hard to make predictions, especially about the future, as Yogi Berra, Niels Bohr, and other luminaries have remarked. But there are already signs that the incoming Trump administration may have some difficulty establishing consistent policies about controversial issues concerning human reproduction.
On the one hand, consider “the conservative blueprint for a second Trump administration.”
The notorious Project 2025’s Mandate for Leadership seeks to delete terms such as “reproductive rights” from “every federal...
By Susan Dominus, The New York Times | 11.30.2024
In the days after Daphna Cardinale delivered her second child, she experienced a rare sense of calm and wonder. The feeling was a relief after so much worrying: She and her husband, Alexander, had tried for three years to conceive...
By Christy Santhosh, Reuters | 11.27.2024
Nov 27 (Reuters) - The U.S. Food and Drug Administration is weighing the need for regulatory action on bluebird bio's (BLUE.O), opens new tab gene therapy for a rare neurological disorder, it said on Wednesday, as the agency probes additional...
